viewGenedrive PLC

Genedrive gets boost as NHS approves antibiotic diagnostic trial


  • Developed and easy-to-use diagnostic device
  • US Department of Defense is a customer 
  • NHS trial to start in November
genedrive device

Quick facts: Genedrive PLC

Price: 18.5 GBX

Market: AIM
Market Cap: £6.29 m


What the company does

Genedrive has developed and is now commercialising a low-cost, rapid, versatile and simple-to-use diagnostic. The device of the same name has a broad range of applications. However, its HCV-ID variant, for detecting hepatitis-c, has received EU regulatory sign-off in the form of CE Certification and has been launched in Africa and the Asia Pacific region. In development is a model for tuberculosis.

So why is this interesting?

Well, the system is able to rapidly process the biologic information from plasma, sputum and buccal swabs. It is easy to use, provides unambiguous results, so doesn’t require specialist knowledge or data interpretation. The company reckons the hand-held Genedrive system is ideal for “low throughput de-centralised labs”.


Financial Position and current trading

For the 12 months ended 30 June, revenue rose to £2.4mln (2018: £1.9mln), broadly in line with forecasts. At £5.2mln, cash was ahead of expectations (2018: £5.8mln).

“The commercialisation of our HCV ID kit is progressing more slowly than we would have hoped,” said chief executive David Budd.

“However, we continue to progress WHO pre-qualified status and the registration of the product in our target countries and so reasonably expect an upturn in demand in the future.

In October, Genedrive received approval from the NHS Health Research Authority to start testing its Antibiotic Induced Hearing (AIHL) test in hospital trials.

The AIHL test identifies a condition that occurs in one in 500 people and can result in profound deafness if a baby with the genotype is given the antibiotic gentamicin.

Every year 90,000 babies in the UK are treated for bacterial infections with gentamicin.




Inflexion points

  • It won its first order from the US Department of Defense (DoD) and it expects more work from the Americans
  • The HCV ID kit is under review by the World Health Organisation for ‘pre-qualified status’
  • Registrations of the hepatitis device is now running at 12 countries 
  • Genedrive’s development of an antibiotic-induced hearing loss test for babies with the NHS is ahead of schedule
  • In October, NHS gave approval for a 1,000 patient trial that will start in November 2019


What the broker says

The company’s broker Peel Hunt reckons the stock is worth 42p (current price 17.5p). 

"Alongside the company’s the better-than-expected traction with the DoD this really demonstrates the platforms wider utility outside of the HCV & TB markets that are commonly associated with genedrive and is an incremental positive to the story".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...



Investor Update: Bezant Resources to sell 80% interest in Mankayan copper...

Headlines from the Proactive UK newsroom. Bezant (LON:BZT) has entered into a conditional deal with a private company based in Singapore to sell an 80% interest in the Mankayan copper-gold project in the Philippines. The deal constitutes a reverse takeover under the Singapore stock exchange...

on 7/10/19

3 min read